P-Xylene

P-Xylene

SCHEMBL5768779

Cc1ccc(C)cc1.Oc1ccncn1

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 3/20 0.40
▸ HSP90AA1 P07900 1/20 0.39
▸ GRM5 P41594 1/20 0.38
▸ TDP1 Q9NUW8 2/20 0.36
▸ CYP19A1 P11511 1/20 0.35
▸ KMT2A Q03164 4/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ P2RX7 Q99572 1/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ STAT1 P42224 1/20 0.34
▸ RPS6KA3 P51812 1/20 0.34
▸ CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29725232 0.88 — —
SCHEMBL102661 0.88 — —
Bromide SCHEMBL28363832 0.85 — —
Hydrochloric Acid SCHEMBL30706493 0.85 — —
Ammonia Solution, Strong SCHEMBL27703525 0.85 — —
Hydrochloric Acid SCHEMBL6215572 0.85 — —
Benzene SCHEMBL10512128 0.83 HSP90AA1 (0.44) HSP90AA1CYP19A1KMT2AMEN1P2RX7
Butane SCHEMBL27731968 0.82 CYP2D6 (0.41) HSP90AA1CYP19A1KMT2AP2RX7NPC1
Sulfuric Acid SCHEMBL27816625 0.77 HSP90AA1 (0.39) HSP90AA1CYP19A1P2RX7ALDH1A1RAB9A
Phenol SCHEMBL27752817 0.76 CA12 (0.48) HSP90AA1TDP1CYP19A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651635-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS Pfizer Limited (GB) 2006-05-03 — — EP claimed
WO-2005009989-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 — — WO claimed
EP-1651635-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS Pfizer Limited (GB) 2006-05-03 — — EP disclosed
WO-2005009989-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 — — WO disclosed
US-20050020587-A1 Nicotinamide derivatives useful as PDE4 inhibitors PFIZER INC 2005-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020587-A1 Nicotinamide derivatives useful as PDE4 inhibitors PDE4A, PDE4B, PDE4D ACHE 945/4885HSP90AA1 4077/4885GRM5 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback